Data de publicação: 10/01/2022 - 14:43
This Friday (January 7), Fiocruz received assent from the National Agency of Sanitary Surveillance (Anvisa) for the alteration in the register of the COVID-19 vaccine (recombinant), which requested the addition of the Foundation as a producer of the Active Pharmaceutical Ingredient (API). After the transference of the AstraZeneca technology and with the approval of Anvisa, the Foundation is now the first institution in the country that is...
Data de publicação: 04/01/2022 - 15:30
A study published on medRXiv, this Wednesday (December 29th), shows that the four vaccines applied in Brazil provide a high degree of additional protection against symptomatic infections and severe cases of COVID-19 in people who had already contracted Sars-CoV-2 previously. The study, led by Julio Croda and Manoel Barral-Neto, Fiocruz researchers, also reinforces the importance of a full vaccination scheme, even for those people.
Data de publicação: 03/01/2022 - 13:05
A third AstraZeneca vaccine dose significantly increases neutralizing antibodies levels against the Ômicron variant (B.1.1.529), a new study indicates. The research was conducted independently by researchers from different institutions, including Fiocruz and Oxford University. And these results were published in preprint form on the bioRxiv platform (Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses) on...
Data de publicação: 03/01/2022 - 12:40
For three consecutive mornings in Brazil, or three nights on the other side of the world, in China, the CAS-Fiocruz webinar on Infectous Diseases brought together researchers from the Foundation and the Chinese Academy of Sciences to exchange information on topics such as COVID-19, vaccines, zika, dengue, and other diseases common to both sides of the globe. The webinar took place on December 14th, 15th, and 16th.
The event opening, on...
Data de publicação: 23/12/2021 - 10:44
As with other COVID-19 immunizers, a booster dose of AstraZeneca vaccine is also required after the complete vaccination schedule. This is indicated by a new study involving Brazil and Scotland, and published in the scientific journal The Lancet on Monday (12/20). The research, of which Fiocruz is part, shows the decrease in vaccine protection over time and in face of the new variants’ emergence.
The assessment, carried out at a time of...
Data de publicação: 23/12/2021 - 09:52
The ties between Fiocruz and the United States Consulate in Rio de Janeiro should become closer next year. On 12/16, the consul Jacqueline Ward and the president of Fiocruz, Nísia Trindade Lima, met at the Official Residence. On the agenda, scientific cooperation between Brazilian and American institutions, the XVI National Malaria Research Meeting and a parallel symposium organized by the Foundation and the National Institute of Allergy...
Data de publicação: 17/12/2021 - 12:41
Continuing an institutional movement to promote science through the dissemination of actions, research, events and courses in other languages, Fiocruz has just incorporated two new courses to the Global Health Training Centre. This time they were "What is Open Science?" and "Open Access", which were translated from Portuguese into English and Spanish. They integrate the series on Open Science developed by the Fiocruz Virtual...
Data de publicação: 17/12/2021 - 12:14
When the World Health Organization (WHO) decided to classify the Omicron strain of the new coronavirus as a variant of concern, it took into account the recommendations of a group of specialists. The so-called Technical Advisory Group on Sars-CoV-2 Evolution (TAG-VE) is a select group of scientists that includes a Brazilian virologist in its line-up: Brazilian researcher Marilda Siqueira, chief of the Laboratory of Measles and Respiratory...
Data de publicação: 16/12/2021 - 09:50
A project resulting from a partnership between the Ministry of Health, Fiocruz, Lacen-PR, and the Federal University of São Paulo (Unifesp) was one of those selected by the U.S. Centers for Disease Control and Prevention (CDC) for funding, as part of the creation of two global networks aimed at fighting antimicrobial resistance. With Ana Paula Assef, head of the Hospital Infection Research Laboratory (LAPIH) at the Oswaldo Cruz Institute...
Data de publicação: 16/12/2021 - 09:23
The first edition of the bulletin on the COVID-19 vaccines' effectiveness in the Brazilian population, from Fiocruz's Vigivac project, was published on Thursday (12/9). The report, which presents analyses of the four vaccines administered in Brazil from January to October 2021, points out that all of them confer a great reduction in the risk of infection, hospitalizations, and death from COVID-19. Considering serious outcomes (...
Data de publicação: 14/12/2021 - 17:24
In a pioneering initiative, the Foundation inaugurates this Monday (13/12), COVID-19 Biobank (BC19-Fiocruz). Located in Rio de Janeiro, at Expansão campus, BC19-Fiocruz will enable the design and conduct of research, technological development and clinical trials related to COVID-19, regardless of the geographic location of human biological material and viruses. With the capacity to store up to one and a half million samples of human and...
Data de publicação: 14/12/2021 - 16:48
A research published today by The Lancet - one of the most prestigious scientific journals focused on the medical field in the world - brought together experts to explain how the economic downturn will affect for years and will be worse in developing countries. Without a consensus for preventive action, families and communities will be disproportionately affected. In the long run, inequalities in health, physical and...
Data de publicação: 14/12/2021 - 16:28
Unit focused on clinical research, education, referral services and assistance in infectious diseases. Integrates the Clinical Research Network.
- Medical Care Reference in infectious diseases, including outpatient appointments, tests, hospitalization and day hospital. There are treated patients with HIV / AIDS, HTLV, sexually transmitted diseases (STDs), Chagas disease, toxoplasmosis, leishmaniasis, mycoses (sporotrichosis,...
Unidades e escritórios
Data de publicação: 13/12/2021 - 17:59
Designated by the United Nations, December 12th is celebrated every year as International Universal Health Coverage Day. The theme this year is Leave no one’s health behind: Invest in Health Systems for All - an issue that gained even more significance as the COVID-19 pandemic rolled on. This year’s campaign will feature a video showing people from all over the world who have shown leadership and vision in this matter, the so-called...
Data de publicação: 10/12/2021 - 13:11
Fifteen years after visiting Fiocruz as a tourist, Pietro Lazzeri returned to the Foundation on Tuesday (12/07), this time as Switzerland ambassador. In office for six months, he met with Fiocruz members at the Fiocruz Global Health Center (CRIS/Fiocruz), where he proposed to expand technical and scientific cooperation. He also visited Bio-Manguinhos, where he found out that some of the machines used in the production of the COVID-19 vaccine...
Data de publicação: 10/12/2021 - 12:09
For one week Fiocruz will be at Expo Dubai. Starting on December 28th, visitors will be able to learn a little more about the Foundation's work and even take a virtual tour of Campus Manguinhos at the Brazil Pavilion. The World Expo takes place every five years and brings themes such as technology and sustainability. It began on October 1st, surrounded by care so that visitors can have interactive participation, but without crowds.
Data de publicação: 06/12/2021 - 14:57
The Oswaldo Cruz Foundation, by means of the Fio-Schisto, the Translational Research Program in Schistosomiasis, informs that researcher Otávio Pieri, of the Oswaldo Cruz Institute (IOC), was invited to become part of the World Health Organization (WHO) group on schistosomiasis and helminth diseases transmitted through the soil (geo helminth diseases). Fio-Schisto is bound to the Vice-Presidency of Biological Research and Collections....
Data de publicação: 06/12/2021 - 13:46
The search for a coordinated solution to a common problem brought together representatives from Brazil, Argentina, Paraguay, Uruguay, and Bolivia this Tuesday (9/11) in the auditorium of the Immunobiological Technology Institute (Bio-Manguinhos). Organized by the Presidency Pro Tempore of Brazil in Mercosur, the Technical Seminar on Access to COVID-19 Vaccines: National Strategies and Possibilities of Expansion of the Regional Productive...
Data de publicação: 30/11/2021 - 12:23
Last Thursday (25 November) the Oswaldo Cruz Foundation, by means of its Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz), submitted to the Brazilian Health Regulatory Agency (Anvisa) a request of post-registration alteration of its COVID-19 vaccine (recombinant), asking to include the Institute as the manufacturing unit of the Active Pharmaceutical Ingredient (API). Check out this 360º view of the production area for the...
Data de publicação: 30/11/2021 - 11:47
In 2018, the king of the Yoruba people, Ooni of Ife, Oba Adeyeye Enitan Babatunde Ogunwus, visited Fiocruz and introduced the idea of a partnership in the field of traditional medicine and integrative health practices. Because of the COVID-19 pandemic, the conversation was stalled, but it was resumed this Wednesday (November 24th) with a visit of a delegation from the Palace of Ife to the Foundation.
(Photo: Pedro Paulo Gonç...
Data de publicação: 29/11/2021 - 10:28
Severe cases of COVID-19 are related to the ageing of the immune system and to acute immunodeficiency. It is what the new study led by the Oswaldo Cruz Institute (IOC/Fiocruz) and by the Federal University of Rio de Janeiro (UFRJ) shows, published in the academic journal Journal of Infectious Diseases.
By analyzing blood samples of patients that have been hospitalized with the disease, the researchers detected signs of hyperactivity,...
Data de publicação: 25/11/2021 - 13:58
“One mistake, one correction”: according to Carlos Morel, a researcher from the Brazilian state of Pernambuco, former Fiocruz president and current coordinator of the Center for Technological Development in Health (CDTS), this is how the world works. Last Tuesday (23 November), after attending the first meeting of the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), a group formed by the World Health Organization...
Data de publicação: 25/11/2021 - 13:30
The first dose protects, but immunization requires a second dose and varies according to the age group and the time interval between doses. These are some conclusions of the pre-publication study that evaluated the effectiveness of the first dose of the AstraZeneca/Fiocruz vaccine against symptomatic cases of COVID-19 in the population of Complexo da Maré, in Rio de Janeiro (RJ). A 42.4% protection against symptomatic cases was estimated...
Data de publicação: 22/11/2021 - 13:51
With two actions this week, Fiocruz became even more engaged in the fight against Hansen's, a neglected disease that had its situation aggravated during the COVID-19 pandemic. On Wednesday (11/17), the Foundation signed a Cooperation Agreement for joining the global campaign Don't Forget Hansen's Disease, with the state government and other partners, in addition to lighting the castle with purple at night as one of the actions to...